Rob Lasser, MD

Chief Medical Officer

Dr. Lasser is a biopharma executive with over 25 years of experience in the CNS space, spanning clinical practice, academic research, large pharma and biotech. Most recently, he held an executive role at Sage Therapeutics, where he led the development of zuranolone (ZURZUVAE®) in depressive disorders. Before that, he was the Chief Medical Officer at MedDay Pharma. Prior to joining MedDay, he was the Head of Neurodegenerative disorders at Roche, where he oversaw the Phase 2 and 3 programs for gantenerumab through 2017. Earlier in his career, Dr. Lasser held various roles at pharmaceutical companies, including managing the medical launch and lifecycle of lisdexamfetamine (VYVANSE®) at Shire, the first medicine for treating Binge Eating Disorder, the launch of the first atypical antipsychotic RISPERDAL CONSTA® at Johnson & Johnson, and developing iloperidone (FANAPT®) at Novartis in the late 1990’s. Dr. Lasser completed his Geriatric Psychiatry fellowship at the National Institute of Mental Health, and his residency in psychiatry at McLean Hospital. He obtained an M.B.A from the University of Pennsylvania Wharton School of Business, a M.D. from Boston University School of Medicine, and a B.A. in Biochemistry from Dartmouth College.